The organization will promote public awareness of cfDNA-based NIPT, encourage legislation supporting testing, and push for reimbursement policy changes.
Natera alleges that Bio-Reference broke a contract by promoting a NIPS test based on Illumina technology over Panorama.
The revenue surge was largely due to revenues from Bio-Reference Laboratories, which Opko acquired in August 2015.
Following the close of the deal, Opko's diagnostic services will be merged with Bio-Reference's operations.
Bio-Reference Laboratories, Cepheid, Exact Sciences, and NanoString all saw their shares rise in June. Sequenom topped the list of decliners.
The deal is still subject to other closing conditions including the approval of BRL's shareholders.
The firm said that revenues per patient were up 3 percent, while the number of patients served grew 8 percent.
Opko plans to leverage BRL's national marketing, sales, and distribution resources to enhance the sale of its blood-based 4Kscore test for aggressive prostate cancer.
The company has amended and restated a credit facility and a secured revolving note to increase the available borrowing amount for each to up to $120 million.
The company's CEO noted the recent launches of new NGS cancer panels and said that more genomics offerings are planned for the year.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.